Please login to the form below

Not currently logged in
Email:
Password:

J&J profit falls on recall woes

Johnson & Johnson has reported a 23 per cent decline in profit for Q1 2011 in spite of increased revenues, as the company experienced high costs related to product recalls and lawsuit
Johnson & Johnson (J&J) has reported a 23 per cent decline in profit for the first quarter in spite of increased revenues, as the company experienced high costs related to product recalls and lawsuits.  

The company's revenue rose 3.5 per cent to $16.17bn for the quarter. Net income was $3.48bn, or $1.25 per share, down from $4.53bn, or $1.62 per share, in 2010's first quarter, when results were positively affected by a $910m gain related to litigation.

Consumer product sales were down 2.2 per cent to $3.68bn, largely due to the recalls. Prescription drug revenue was up 7.5 per cent globally to $6.1bn, while revenue from medical devices and diagnostics rose 3.3 per cent, to $6.43bn.

"Our pharmaceuticals business demonstrated strong operational sales growth this quarter of over 6 per cent, due to the success of our recently launched products such as Stelara and Simponi and core medicines such Remicade and Prezista," J&J chief financial officer Dominic Caruso said during a conference call. 

"And our consumer healthcare business saw sequential improvements in its operational sales growth versus the fourth quarter of 2010 in various markets, excluding the impact of the plant shutdown and the lower production levels in our McNeil US over-the-counter (OTC) business, where we are making good progress in addressing the manufacturing and quality issues in that business," he added. 

J&J also increased its estimate of costs per share related to recalls this year. "We had previously included in our guidance for 2011 an impact of approximately $0.06 per share from of the ongoing remediation efforts at McNeil," Caruso said. 

"Now that we have finalised the terms of the Consent Decree, we estimate that, that impact will be twice that amount. This results from both the slowdown in sales reflecting the impact on production volumes as we implement the additional quality steps outlined in the Decree, as well as additional investments required in the remediation process."

J&J raised its profit forecast for the year by 10 cents to $4.90 to $5 per share.

20th April 2011

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Say Communications

Influencing positive behaviours and delivering change is what drives us, using thought leadership, education, social and professional engagement and compelling,...

Latest intelligence

Is the pharma business model ready for precision medicine?
Precision medicine promises to revolutionise patient outcomes and reduce costs for industry but is pharma ready for it? Blue Latitude Health co-founder Head of Strategy Fred Bassett explores the challenges...
ABPI2018
The NHS and ABPI at 70: inching closer to the triple win
The NHS and UK pharma’s ABPI both turn 70 this year. After years of transactional relationships, there’s a will to work more closely - but friction on prices and value...
What pharma marketers can learn from behavioural science
Pharma behavioural science and traditional emotional marketing create a powerful mix of techniques that have impact on real lives....

Infographics